CoChat

Engineered in vitro multi-cell type ventricle model generates long-term pulsatile flow and modulates cardiac output in response to cardioactive drugs

Open access
Kuckelkorn, Christoph, Aksoy, Ebru, Stojanovic, Natalija, Oulahyane, Laila, Ritter, Mira, Pfannkuche, Kurt, Fischer, Horst · 2025 · Advanced Healthcare Materials

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index; 35 of the 50 sources its claims cite were checked for support.

Abstract

Abstract Cardiac in vitro models serve as promising platforms for physiological and pathological studies, drug testing, and regenerative medicine. This study hypothesizes that immobilizing cardiomyocytes derived from human induced pluripotent stem cells (iPSC‐CMs) on a biofunctionalized, hemispherical membrane can generate pulsatile flow through synchronized contractions, thus offering as an in vitro left ventricle model. To test this, a ventricle using a polydimethylsiloxane (PDMS) membrane coated with polydopamine and laminin 511 E8 fragments is engineered. Human iPSC‐CMs are cultured on these membranes, alone or in co‐culture with cardiac fibroblasts or endothelial cells, for 28 and 14 days, respectively, in a newly developed bioreactor. Flow measurements track beating and flow generation, while drug response, cardiac gene expression, and cell morphology are analyzed. The engineered ventricles maintain continuous beating and flow, achieving a theoretical cardiac output of up to 4 µL min −1 over 28 days, indicating stable cell adhesion and synchronized contraction. Cardiomyocytes respond to cardioactive drugs (carbachol, isoproterenol) and show expected changes in heart rate and cardiac output. In conclusion, the results demonstrate that the proposed engineered ventricle can serve as an in vitro left ventricle model by supporting cardiomyocyte culture and differentiation, generating long‐term stable flow, and responding physiologically to cardioactive drugs.

Overview

CoChat Summary

## TL;DR

The paper builds a hemispherical PDMS-based in vitro left ventricle model using human iPSC-derived cardiomyocytes, with polydopamine and laminin E8 511 fragments enabling long-term attachment and synchronous contraction. The engineered ventricles generated pulsatile flow for up to 28 days, reached a theoretical cardiac output of up to 4 µL min−1, and responded to isoproterenol and carbachol with expected changes in beating and output.

## Key findings

  • Polydopamine plus laminin E8 511 outperformed 3MOBS for cardiomyocyte attachment: the paper reports cell densities about 5–10 times higher than after 3MOBS functionalization, with functional beating up to 14 days post-seeding in PDA-treated groups.
  • The monoculture ventricle showed stable function through day 28; mean beating frequency ranged from 69.6 bpm on day 7 to 97.5 bpm on day 21, and theoretical cardiac output ranged from 0.5 µL min−1 on day 28 to 1.2 µL min−1 on day 14.
  • The model’s cardiomyocytes showed a more ventricular phenotype than controls: MYH7 and MYL2 were upregulated by factors of 8.6 and 47.4, respectively, and GJA1 was upregulated by 20.6 relative to control.
  • Drug testing showed expected pharmacology: after 60 min of treatment, isoproterenol (10 µM) increased frequency by 30.6–45.9% and theoretical cardiac output by 98.2–189.1%, while carbachol (10 µM) decreased frequency by 12.6–23.7% and theoretical cardiac output by 44.0–72.7%.

## Methods

  • The study engineered a hemispherical PDMS membrane and compared surface functionalization methods, including polydopamine, UV/acid pretreatments, and 3MOBS, then coated the selected surface with laminin E8 511 for cardiomyocyte attachment.
  • Human iPSC-derived cardiomyocytes were cultured either alone for 28 days or in co-culture with cardiac fibroblasts or cardiac microvascular endothelial cells for 14 days; the paper also used human primary cardiac fibroblasts and endothelial cells.
  • Function was assessed in a custom bioreactor that measured flow from membrane contraction; analyses included brightfield microscopy, immunofluorescence, flow cytometry, qPCR, and drug-response experiments with isoproterenol and carbachol.

## Limitations

  • The authors state that co-cultures could only be cultivated until day 14 due to overgrowth, so long-term multi-cell-type maintenance was not achieved.
  • The paper says the model is not yet tailored for patient-specific applications because it does not account for the genetic or phenotypic variability of patient-derived cells.
  • Evident from the text: some comparisons are limited by different media and culture durations between monoculture and co-culture conditions, and some treatment groups had small sample sizes (for example, n = 5 monoculture ventricles and n = 3 co-culture measurements).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1002/adhm.202403897

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 a) Schematic depiction of the bioreactor housing the biofunctionalized hemispherical PDMS membrane. Contraction of the immobilized cardiomyocytes on the membrane induces contraction of the membrane itself, resulting in volume displacement that can be quantified using a flow sensor. b) Time scale of the experiment to measure the contraction dynamics of the engineered ventricles. c) CAD exploded view of the seeding reactor, highlighting its individual components. d) CAD cross section of the seeding reactor with the area where the single cell suspension is added marked. e) Image of the rotating seeding reactor showing the 52.5° inclination angle and the rotation axis of the apparatus, which ensures uniform distribution of cells over the entire membrane. f) Photograph of the long‐term cultivation bioreactor, optimized for continuous flow measurements. g) CAD exploded view of the long‐term cultivation bioreactor, providing a detailed visualization of its structural elements.
Figure 1 a) Schematic depiction of the bioreactor housing the biofunctionalized hemispherical PDMS membrane. Contraction of the immobilized cardiomyocytes on the membrane induces contraction of the membrane itself, resulting in volume displacement that can be quantified using a flow sensor. b) Time scale of the experiment to measure the contraction dynamics of the engineered ventricles. c) CAD exploded view of the seeding reactor, highlighting its individual components. d) CAD cross section of the seeding reactor with the area where the single cell suspension is added marked. e) Image of the rotating seeding reactor showing the 52.5° inclination angle and the rotation axis of the apparatus, which ensures uniform distribution of cells over the entire membrane. f) Photograph of the long‐term cultivation bioreactor, optimized for continuous flow measurements. g) CAD exploded view of the long‐term cultivation bioreactor, providing a detailed visualization of its structural elements.CC BY · PubMed Central
Figure 2 a) Immunofluorescence micrographs showcasing cardiomyocytes adhered to 2D PDMS samples following various functionalization techniques, including crosslinking of proteins with polydopamine (PDA) and 3MOBS silane, after a 14‐day period (scale bar = 50 µm). b) Quantification of adherent cardiomyocytes count by nuclei staining on different functionalized PDMS (the significance levels are shown in Table S4, Supporting Information, for the sake of clarity). c) Contact angle measurements of PDMS following various functionalization methodologies (significance is only displayed within each group between day 1 and 21. Comprehensive comparisons across all groups can be referenced in Table S5, Supporting Information). Assessment of the frequency d) and amplitude of optical displacement e) corresponding to cardiomyocyte cultures beating patterns (only groups are displayed, where cardiomyocytes were beating synchronized once during the experiment). The statistical analyses were carried out using one‐way ANOVA (b) and two‐way ANOVA (c–e). n = 3 experiments for b), n = 9 technical replicates for c), n = 4 experiments for d,e). Significance levels of * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 were defined.
Figure 2 a) Immunofluorescence micrographs showcasing cardiomyocytes adhered to 2D PDMS samples following various functionalization techniques, including crosslinking of proteins with polydopamine (PDA) and 3MOBS silane, after a 14‐day period (scale bar = 50 µm). b) Quantification of adherent cardiomyocytes count by nuclei staining on different functionalized PDMS (the significance levels are shown in Table S4, Supporting Information, for the sake of clarity). c) Contact angle measurements of PDMS following various functionalization methodologies (significance is only displayed within each group between day 1 and 21. Comprehensive comparisons across all groups can be referenced in Table S5, Supporting Information). Assessment of the frequency d) and amplitude of optical displacement e) corresponding to cardiomyocyte cultures beating patterns (only groups are displayed, where cardiomyocytes were beating synchronized once during the experiment). The statistical analyses were carried out using one‐way ANOVA (b) and two‐way ANOVA (c–e). n = 3 experiments for b), n = 9 technical replicates for c), n = 4 experiments for d,e). Significance levels of * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 were defined.CC BY · PubMed Central
Figure 3 a) Exemplary flow measurement of an engineered ventricle with representation of the analyzed parameters b) Analysis of beating frequency, theoretical cardiac output, stroke volume and the max. volume flow over the period of 28 days of engineered ventricle seeded only with cardiomyocytes. No statistical significance levels were found by one‐way ANOVA between the different days in each analyzed parameter. Data of n = 5 engineered ventricles were used for statistical analysis. Significance levels of * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 were defined. c) Immunofluorescence staining of alpha actinin 2 (green) and cardiac troponin T (red) and nuclei (blue) of cardiomyocytes from the engineered ventricle. Scale bar = 50 µm. d) Characteristic section of merged image which is displayed enlarged for a better visibility. e) Flow cytometry analysis of cardiomyocytes after dissociation (day 0), the engineered ventricle, TCP (tissue culture plate), and CM sphere cultures at day 28 for alpha‐actinin 2 expression.
Figure 3 a) Exemplary flow measurement of an engineered ventricle with representation of the analyzed parameters b) Analysis of beating frequency, theoretical cardiac output, stroke volume and the max. volume flow over the period of 28 days of engineered ventricle seeded only with cardiomyocytes. No statistical significance levels were found by one‐way ANOVA between the different days in each analyzed parameter. Data of n = 5 engineered ventricles were used for statistical analysis. Significance levels of * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 were defined. c) Immunofluorescence staining of alpha actinin 2 (green) and cardiac troponin T (red) and nuclei (blue) of cardiomyocytes from the engineered ventricle. Scale bar = 50 µm. d) Characteristic section of merged image which is displayed enlarged for a better visibility. e) Flow cytometry analysis of cardiomyocytes after dissociation (day 0), the engineered ventricle, TCP (tissue culture plate), and CM sphere cultures at day 28 for alpha‐actinin 2 expression.CC BY · PubMed Central
Figure 4 Expression of cardiomyocyte‐related genes, as well as genes associated with gap junctions and mitochondrial activity, in cardiomyocytes from engineered ventricles, tissue culture plates, and CM sphere cultures were compared to those in dissociated cells at day 0. ISL1 expression was not detected in the engineered ventricle group. Statistical analyses were performed using one‐way ANOVA test with n = 3 technical replicates for each analysis. Significance levels of * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 were defined.
Figure 4 Expression of cardiomyocyte‐related genes, as well as genes associated with gap junctions and mitochondrial activity, in cardiomyocytes from engineered ventricles, tissue culture plates, and CM sphere cultures were compared to those in dissociated cells at day 0. ISL1 expression was not detected in the engineered ventricle group. Statistical analyses were performed using one‐way ANOVA test with n = 3 technical replicates for each analysis. Significance levels of * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 were defined.CC BY · PubMed Central
Figure 5 a) Immunofluorescence of co‐culture of hiPSC‐CMs with hCF on engineered ventricles. b) Immunofluorescence of co‐culture of hiPSC‐CMs with hCMEC on engineered ventricles. c) Beating analysis of engineered ventricles seeded with hiPSC‐CMs with hCF. d) Beating analysis of engineered ventricles seeded with hiPSC‐CMs with hCMEC. e) Expression levels of cardiomyocyte‐related genes, as well as genes associated with gap junctions and mitochondrial activity, in cardiomyocytes isolated from engineered ventricles co‐cultured with hCFs and hCMECs using MACS. Statistical analyses were performed using one‐way ANOVA for c) and d) as well as two‐way ANOVA for e). n = 3 engineered ventricles at c) and d). n = 3 technical replicates for e). Significance levels of * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 were defined.
Figure 5 a) Immunofluorescence of co‐culture of hiPSC‐CMs with hCF on engineered ventricles. b) Immunofluorescence of co‐culture of hiPSC‐CMs with hCMEC on engineered ventricles. c) Beating analysis of engineered ventricles seeded with hiPSC‐CMs with hCF. d) Beating analysis of engineered ventricles seeded with hiPSC‐CMs with hCMEC. e) Expression levels of cardiomyocyte‐related genes, as well as genes associated with gap junctions and mitochondrial activity, in cardiomyocytes isolated from engineered ventricles co‐cultured with hCFs and hCMECs using MACS. Statistical analyses were performed using one‐way ANOVA for c) and d) as well as two‐way ANOVA for e). n = 3 engineered ventricles at c) and d). n = 3 technical replicates for e). Significance levels of * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 were defined.CC BY · PubMed Central
Figure 6 Exemplary response of the engineered ventricles to isoproterenol (ISO) a) and carbachol (CCH) b), and quantification of the beating frequency c), theoretical cardiac output d), stroke volume e), and max. volume flow f) in comparison to pure hCM culture and co‐cultures with hCFs and hCMECs. No significant differences were found by statistical analysis within a drug group. c–f): statistical analyses were performed using two‐way ANOVA with n = 4 engineered ventricles, and no significant differences were found between different culture groups of each treatment. Significance levels of * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 were defined.
Figure 6 Exemplary response of the engineered ventricles to isoproterenol (ISO) a) and carbachol (CCH) b), and quantification of the beating frequency c), theoretical cardiac output d), stroke volume e), and max. volume flow f) in comparison to pure hCM culture and co‐cultures with hCFs and hCMECs. No significant differences were found by statistical analysis within a drug group. c–f): statistical analyses were performed using two‐way ANOVA with n = 4 engineered ventricles, and no significant differences were found between different culture groups of each treatment. Significance levels of * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 were defined.CC BY · PubMed Central

Verification

Claims the paper makes

23 Valid · 5 Not valid · 5 Not checked · 94 Own results and interpretations

64 more claims · 2 with their cited sources checked

Create a free account to see all 127 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 46
  • Probably not a substantial claim. 17
  • The quote only partly states this claim. 3

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 6

  1. Virani S. S., 2020, Circulation, 9
  2. Drakhlis L., 2023, Dis. Model Mech., 5
  3. Gupta S., 2018, Tissue Eng. BioNanoSci., 3, 868
  4. Tsuzuki T., 2022, Materials, 6
  5. Ostchega Y., 2011, Natl Health Stat Report., 1, 1
  6. Zhou Y., 2024, Biologics, 18, 115

Cited by

See all 3

Metadata

Authors
Kuckelkorn, C., Aksoy, E., Stojanovic, N., Oulahyane, L., Ritter, M., Pfannkuche, K., & Fischer, H.
Affiliations
  • Universitätsklinikum Aachen (DE)
  • University of Cologne (DE)
Corresponding author
Fischer, Horst
Venue
Advanced Healthcare Materials
Publisher
Wiley
Published
2025-02-13
Volume
14
Issue
10
Pages
e2403897-e2403897
ISSN
  • 2192-2640 (ISSN-L)
  • 2192-2659
OpenAlex
W4407426312
Cited by
3
References
55
Citations by year
2026: 3
FWCI
2.80
Type
journal article
Language
en
Open access
Licence
Locations
  • Advanced Healthcare Materials (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RWTH Publications (RWTH Aachen) (submittedVersion, other-oa)
Funders
RWTH Aachen University
Topics
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
Keywords
iPSC-derived cardiomyocytes, pulsatile flow, cardiac output, polydopamine coating, PDMS membrane, bioreactors, cardioactive drugs, carbachol, isoproterenol, heart rate response, cardiomyocyte beating
MeSH terms
Cardiac Output, Dimethylpolysiloxanes, Fibroblasts, Heart Ventricles, Humans, Pulsatile Flow, Coculture Techniques, Tissue Engineering, Myocytes, Cardiac, Induced Pluripotent Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.